IL17A and cancer: Other agents used were etanercept (n = 7), adalimumab (n = 2), ustekinumab (n = 2), brodalumab (n = 3), and ixekizumab (n = 2) (Table 1). In all cases, the treatments were effective and well tolerated, with follow-up durations ranging from 6 months to 5 years [2,3]. The IL-17/IL-23 axis (TH17 pathway) has also been implicated in the pathophysiology of transplant rejection, suggesting that IL-17 and IL-23 may be promising therapeutic targets for preventing immunological complications in this setting [4]. Our case is further distinguished by the patient's recent history of cancer recurrence.